Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Unity Biotechnology, Inc. UBX
$2.72
-$0.05 (-1.81%)
На 18:01, 12 мая 2023
+2 841.18%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
39829549.00000000
-
week52high
18.50
-
week52low
1.46
-
Revenue
236000
-
P/E TTM
-1
-
Beta
0.69152100
-
EPS
-6.71000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 20:00
Описание компании
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Mizuho | Buy | Buy | 16 авг 2022 г. |
| Citigroup | Buy | Buy | 15 авг 2022 г. |
| Citigroup | Buy | Buy | 17 мая 2022 г. |
| Roth Capital | Buy | Neutral | 04 янв 2022 г. |
| Mizuho | Buy | Neutral | 10 ноя 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 09 ноя 2022 г. |
| Wedbush | Outperform | Outperform | 02 ноя 2022 г. |
| Mizuho | Buy | Buy | 16 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Dananberg Jamie | D | 64242 | 863 | 02 февр 2023 г. |
| Ghosh Anirvan | D | 92235 | 2573 | 02 февр 2023 г. |
| Ghosh Anirvan | D | 94808 | 1140 | 30 янв 2023 г. |
| Ghosh Anirvan | D | 95948 | 1274 | 14 дек 2022 г. |
| Dananberg Jamie | D | 65105 | 1016 | 14 дек 2022 г. |
| Nguyen Alexander Hieu | A | 65000 | 65000 | 18 ноя 2022 г. |
| Dananberg Jamie | A | 65000 | 65000 | 18 ноя 2022 г. |
| Ghosh Anirvan | A | 200000 | 200000 | 18 ноя 2022 г. |
| Sullivan Lynne Marie | A | 80000 | 80000 | 18 ноя 2022 г. |
| Ghosh Anirvan | D | 97222 | 1099 | 03 ноя 2022 г. |
Новостная лента
Unity (UNX) Down on Disappointing Results From Wet AMD Study
Zacks Investment Research
28 мар 2023 г. в 16:45
Unity's (UBX) phase II ENVISION study on UBX1325 fails to meet the non-inferiority threshold compared to aflibercept through 24 weeks in the wet AMD study.
Why Is Unity Biotechnology (UBX) Stock Down 52% Today?
InvestorPlace
27 мар 2023 г. в 12:00
Unity Biotechnology (NASDAQ: UBX ) stock is taking a beating on Monday after revealing results from its Phase 2 clinical trial of UBX1325. UBX1325 is a treatment in development by the company that it's testing for use with patients suffering from wet age-related macular degeneration ( AMD ).
Unity Biotechnology (UBX) Stock Pops on Positive Study Data
InvestorPlace
01 ноя 2022 г. в 12:45
Unity Biotechnology (NASDAQ: UBX ) stock is gaining on Tuesday after the company released results from a Phase 2 clinical trial of UBX1325. UBX1325 is the company's treatment in development to treat patients dealing with diabetic macular edema (DME).
Unity Biotechnology: Share Consolidation On The Back Of Positive Trial Results
Seeking Alpha
24 окт 2022 г. в 08:15
A small cap biotech targeting diseases of ageing, with a lead compound focusing on ophthalmology that recently reported positive trial results. Not overly reliant on debt and has reported some revenues with relatively stable overall financials.
All You Need to Know About UNITY Biotechnology, Inc. (UBX) Rating Upgrade to Strong Buy
Zacks Investment Research
10 окт 2022 г. в 13:32
UNITY Biotechnology, Inc. (UBX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.